Last quarter I ran a cost model on four unrelated purchase requests: an electric Permobil wheelchair, a hemodialysis machine, a dental implant program, and a small PCR lab. People asked why those sat in one spreadsheet. The reason: all four were the same decision. Do we buy and operate the asset, or do we pay someone else every time the asset is used?
I am the procurement manager for a medical purchasing cooperative that supplies rehab equipment and diagnostics to small hospitals, clinics, and home care agencies. I have managed a $2.7 million annual budget for eight years. My real job is making sure the invoice after year one does not hurt more than the first purchase order.
So this article is not a brand comparison. It is the comparison that comes first: capital asset vs. per-use service.
The decision under every quote
The wheelchair folder contained a request for an electric Permobil wheelchair. The spec included the Permobil M300 manual mode. At first glance, it looked like one more power chair quote. In practice, the manual mode changed who could handle the chair, what kind of training the caregiver needed, and whether we needed a backup plan for transport.
The hemodialysis machine folder was different. A small clinic wanted to bring dialysis back in-house instead of sending every patient to a regional center. The dental implant folder was about a dentist who wanted to stop referring implant cases. The PCR folder started with a lab manager asking how to price in-house testing.
Four different specialties. One spreadsheet logic.
Do not ask, “Can we afford the machine?” Ask, “If this machine sits idle for 30 days, what does it cost? And if we buy the service per case, what do we pay when volumes spike unexpectedly?”
Entry cost is only the ticket, not the trip
The first mistake is comparing unit prices. I compare entry requirements.
For the electric Permobil wheelchair, the entry requirement was not just the chair. It was setup, programming, battery condition, and caregiver training. The Permobil M300 manual mode was not an automatic checkbox. In the first quote, we saw the chair price. We did not see the extra programming visit or the caregiver training session. That reminded me of something that happened in 2023: another vendor promised “free setup” on a power wheelchair, and then we paid $450 for a second visit because no one defined what setup included. The setup was free. The clarification was not.
For the hemodialysis machine, the same pattern appeared. A machine can look reasonably priced, but the real entry cost is the water treatment system, the room layout, the backup power plan, and the training protocol. If the water loop is not ready, the machine is expensive furniture. That line item almost got missed in the rural clinic project.
A dental implant program has a similar trap. You do not buy one implant. You buy a range of lengths, diameters, healing abutments, drivers, and spare parts. If you stock too little, you cancel surgeries. If you stock too much, you tie up cash. Either way, the unit price of the implant itself was never the real cost.
And PCR? The entry cost is not the thermal cycler. It is the extraction system, pipettes, certified technician time, freezer space, positive controls, and a process for repeat testing. The instrument is often the smallest part of the startup bill.
Per-unit cost hides the cost of a successful result
The real number is not cost per order. It is cost per successful, usable result.
A successful wheelchair delivery is not a signed delivery receipt. It is a patient who uses the chair safely after thirty days. A successful hemodialysis session is one that runs without an equipment alarm and with all the right consumables available. A successful dental implant case is one where the surgical kit was complete and the implant was not contaminated. A successful PCR run includes valid controls and no unexplained contamination.
That changes how I compare.
How does PCR work in a procurement sense? PCR stands for polymerase chain reaction. In short, thermal cycling makes copies of a target DNA sequence. Each cycle doubles the target if the reaction works. That is why reagent costs can look small. The hidden costs are sample preparation, quality controls, repeat runs, and interpretation. A vendor can quote a low price per PCR test, but if controls are billed separately or failed runs are not covered, the per-successful-result price goes up.
The same logic applies to the hemodialysis machine. The consumables for one dialysis treatment do not end at the dialyzer. There are lines, acid and bicarbonate bath solutions, heparin, caps, dressing sets, and waste handling. If a per-use outsourced contract includes all of that, it may look expensive. If an in-house model only counts the machine depreciation and forgets the rest, it will look cheap and then surprise you.
What happens when something fails
This is the dimension that most people ignore until they are standing in a stored room with a non-working device.
When a power wheelchair has a joystick failure, who listens? If you own it, you are the listener. When the Permobil M300 manual mode is not working correctly, a caregiver cannot push the chair safely. That is not a small annoyance. It is a safety problem. I have learned to ask every mobility vendor how many service technicians they have within a four-hour radius. That question matters more than a brochure feature.
When a hemodialysis machine stops mid-treatment, the cost is clinical, not just mechanical. An in-house machine needs a backup plan for urgent repair. An outsourced dialysis center may be slower to respond, but the financial risk of device downtime belongs to the vendor. That distinction matters to a small clinic.
I kept second-guessing our PCR decision after we signed the lease. What if contamination appeared in the first batch? I did not relax until three consecutive runs passed with clean controls. Then I looked at the old send-out bills and noticed a line for repeat samples. That paid for about half of our annual instrument service contract. I was glad we had a clear repeat-test policy before the analyzer arrived.
The break-even surprise
The surprising part of my model was PCR. Many people assume in-house PCR is automatically cheaper. It is not.
At low volume, a send-out lab wins because the fixed cost of instrument service and controls is spread over too few tests. In our 2024 model, the in-house route did not beat the per-use PCR price until we projected around 700 reportable tests per year. Below that volume, the per-use route was actually the lower-cost option. Above it, in-house PCR became clearly cheaper. That is the kind of threshold a small clinic needs to estimate before signing anything.
The same pattern applied to the dental implant decision. At twenty cases a year, referring out was still cheaper than carrying a wide implant inventory and paying for surgical training. At sixty cases a year, in-house placement changed the calculation because the staff already knew the workflow. The break-even point was not the price of the implant component. It was the number of cases needed to keep the team competent and the inventory moving.
So which should you choose?
I do not have a universal answer. That is the point.
Own the asset when:
- The projected volume is above the break-even point within the first year.
- Your staff can handle the complexity without depending on one person.
- You need fast response times and cannot wait for an external provider.
Pay per use when:
- You are testing a new service line and the volume is uncertain.
- The clinical team is not ready to support the equipment.
- Your real need is flexibility, not asset ownership.
There is also a procurement bias I will admit. I favor vendors who take small orders seriously. A vendor who treated our first $240 order badly never got our $80,000 order. Small clinics and pilot projects deserve honest per-use pricing, not minimum-volume traps. Good equipment suppliers do not punish small starts.
Final checklist before you approve
Whether it is an electric Permobil wheelchair, a hemodialysis machine, a dental implant stocking decision, or a PCR lab, I use the same checklist.
First, compare the two business models side by side. Second, calculate cost per successful result, not cost per quote. Third, write down the failure cost. Fourth, ask what the volume will look like after eighteen months.
And treat every vendor claim like an advertising claim. Per FTC guidance, claims should be truthful and substantiated. I am not citing the FTC for legal drama. I am saying this: if “all-inclusive” cannot be shown in an itemized quote, it is not an all-inclusive price. Get the line item. Then make the decision.
That spreadsheet with the wheelchair, dialysis machine, dental implant, and PCR request? It did not give me one answer. It gave me four better questions.
